Cortical amino acidergic pathways in Alzheimer's disease
- PMID: 2824688
Cortical amino acidergic pathways in Alzheimer's disease
Abstract
Amino acidergic neurons in the cerebral cortex are the most abundant neuronal types. The inhibitory amino acid, GABA, is the neurotransmitter of many cortical interneurons, particularly those in layers III and IV of cerebral cortex. The excitatory amino acids, glutamate and aspartate, are the likely neurotransmitters of corticofugal, corticocortical association and hippocampal pyramidal neurons. In dementia of the Alzheimer type (DAT), there is only mild to moderate loss of GABAergic neurons and there is only a mild reduction in postsynaptic GABAA receptors. The unique bicuculline-insensitive baclofen-sensitive GABAB receptor is affected in DAT and is reduced by about 60-70% in outer layers of cerebral cortex and hippocampus. Presynaptic markers of glutamate neurons (glutamate levels and glutamate sodium-dependent binding) are reduced 25-80% in cortex and hippocampus of DAT brain. Likewise, glutamate postsynaptic receptors, particularly the NMDA-sensitive receptor, are markedly reduced in DAT cortex and hippocampus. These alterations suggest that glutamatergic pyramidal cells are especially vulnerable in DAT brain.
Similar articles
-
Plasticity and neurotransmitter receptor changes in Alzheimer's disease and experimental cortical infarcts.Arzneimittelforschung. 1995 Mar;45(3A):361-6. Arzneimittelforschung. 1995. PMID: 7763327
-
Presynaptic GABAA receptors facilitate spontaneous glutamate release from presynaptic terminals on mechanically dissociated rat CA3 pyramidal neurons.Neuroscience. 2006;138(1):25-35. doi: 10.1016/j.neuroscience.2005.11.001. Epub 2005 Dec 27. Neuroscience. 2006. PMID: 16378694
-
A postmortem study of amino acid neurotransmitters in Alzheimer's disease.Ann Neurol. 1986 Nov;20(5):616-21. doi: 10.1002/ana.410200510. Ann Neurol. 1986. PMID: 2878639
-
Do GABAA and GABAB inhibitory postsynaptic responses originate from distinct interneurons in the hippocampus?Can J Physiol Pharmacol. 1997 May;75(5):520-5. Can J Physiol Pharmacol. 1997. PMID: 9250387 Review.
-
Clinical correlations of the neurobiological changes of aging.Ann Med Interne (Paris). 1990;141 Suppl 1:3-6. Ann Med Interne (Paris). 1990. PMID: 1982048 Review.
Cited by
-
Neuroimmunology, women scientists and dogma.Nat Immunol. 2024 Mar;25(3):377-378. doi: 10.1038/s41590-024-01767-3. Nat Immunol. 2024. PMID: 38429451 No abstract available.
-
Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques.Front Neuroanat. 2009 Nov 20;3:28. doi: 10.3389/neuro.05.028.2009. eCollection 2009. Front Neuroanat. 2009. PMID: 19949482 Free PMC article.
-
Hippocampal glutamate NMDA receptor loss tracks progression in Alzheimer's disease: quantitative autoradiography in postmortem human brain.PLoS One. 2013 Nov 28;8(11):e81244. doi: 10.1371/journal.pone.0081244. eCollection 2013. PLoS One. 2013. PMID: 24312282 Free PMC article.
-
Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks.Neurobiol Aging. 2012 Jan;33(1):205.e1-18. doi: 10.1016/j.neurobiolaging.2010.08.012. Epub 2010 Oct 13. Neurobiol Aging. 2012. PMID: 20947216 Free PMC article.
-
GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease.Front Cell Neurosci. 2014 Jun 25;8:167. doi: 10.3389/fncel.2014.00167. eCollection 2014. Front Cell Neurosci. 2014. PMID: 24987334 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical